St. Jude Medical (NYSE:STJ) announced Tuesday that its renal denervation technology was effective in lowering blood pressure of patients whose hypertension remained stubbornly high despite being on many medications. The EnligHTN technology was effective in that, on average, patients saw their systolic blood pressure lowered 28 mmHg points after 30 days of treatment. The effect was […]
UPDATE: Scroll down to see St. Jude Medical’s detailed statement. Dr. Robert Hauser will not make the list of St. Jude Medical’s most favorite cardiologists any time soon. Hauser, a prominent cardiologist from Minneapolis Heart Institute known for studying how heart devices function, has concluded that St. Jude Medical’s (NYSE:STJ) highly touted Durata lead is […]
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Vascular Solutions (NASDAQ: VASC) believes that it can make a real business out of a product line that St. Jude Medical (NYSE:STJ) discontinued in July 2011. On Friday, the Maple Grove, Minnesota company, announced that it was buying St. Jude Medical’s Venture catheter product for $3 million, paying $2.25 million upfront and $750,000 to be paid […]
Looks like the Food and Drug Administration is not buying St. Jude Medical’s (NYSE:STJ) insistence that the Durata ICD lead is safe. While some have argued that the Durata leads are very similar in design to the recalled Riata and Riata ST defibrillator leads and will fail too, St. Jude has long fought the notion […]
If people are looking for confirmation that the global cardiac rhythm management market has declined as much as it could and will fall no further, they have to wait a while. A week ago St. Jude Medical CEO Dan Starks admitted that the company has been routinely too optimistic in predicting the bottom of the […]
St. Jude Medical (NYSE:STJ) may have performed better than expected in the cardiac rhythm management business in the second quarter, but that doesn’t necessarily mean the company is confident about seeing a rosier picture around the corner. The Minnesota medical device company reported Wednesday that revenue fell 2 percent to $1.41 billion from $1.46 […]
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
St. Jude Medical’s (NYSE:STJ) Durata leads have held up quite well so far despite the notion that many have that the leads are similar in design to the recalled Riata leads and will therefore fail. The company chalks up Durata’s resilience to lead abrasion to a polymer insulation called Elast-Eon that St. Jude has re-branded […]
Given how St. Jude Medical (NYSE:STJ) has promoted the near infallibility of the Durata defibrillator’s lead insulation, it was imperative that executives move fast when a report emerged that cables had poked through their insulation in one patient. That single report had caused the stock to slide 6 percent in a day. On Friday, just […]
St. Jude Medical (NYSE:STJ) announced Monday that the U.S. Food and Drug Administration has cleared a vascular plug for use in procedures that selectively block abnormal blood vessels. St. Jude Medical’s AMPLATZER Vascular Plug 4 can be used with a standard catheter in lieu of an embolization coil. As such, it is a first of […]
St. Jude Medical (NYSE:STJ) is having a bad week. An unconfirmed report about lead wires poking through their insulation on its newer, apparently more resistant ICD lead saw the stock slide 6 percent on Tuesday. An analyst called it a overreaction, though there is cold comfort in that. And now, the Minnesota medical device company […]
Gabby Everett, the site director for BioLabs Pegasus Park, offered a tour of the space and shared some examples of why early-stage life science companies should choose North Texas.
Two events this week prompted investors to disproportionately reward and punish stocks of two medical technology companies: Edwards Lifesciences (NYSE:EW) and St. Jude Medical (NYSE:STJ). One piece of news was largely expected — a panel at the U.S. Food and Drug Administration gave a thumbs up to the expanded indication for Edwards Lifesciences’ SAPIEN transcatheter […]
UPDATE: An earlier version of the story incorrectly reported that the patient with the Durata lead that had externalized conductors died. The FDA Maude adverse event database does show that patients implanted with Durata leads have died but those were not connected to device problems. Externalized conductors is the failure that led to the recall […]
St. Jude Medical (NYSE:STJ) has agreed to pay $3.65 million to settle a Department of Justice inquiry into the company’s alleged practice of overstating the price of its replacement defibrillators and pacemakers. The Justice Department announced Thursday that the settlement resolves allegations related to the company’s warranty discount program. St. Jude marketed a discount […]
When it comes to commercialization efforts of renal denervation therapy, St. Jude Medical (NYSE:STJ) is behind Medtronic (NYSE:MDT). But St. Jude Medical is hoping that slow and steady may still win the race in the quest to use this novel treatment in patients whose high blood pressure is not controlled by medication. The device maker announced […]
Life science current events this week include J&J and MDT's contrasting acquisition strategies, the transcatheter valve replacement market and cardiovascular disease medical device companies.